6 O
ADVERSE O
REACTIONS O
EXCERPT O
: O
The O
most O
common O
adverse O
reactions O
( O
> O
= O
10 O
% O
) O
across O
all O
studies O
with O
GATTEX O
are O
abdominal O
pain O
, O
injection O
site O
reactions O
, O
nausea O
, O
headaches O
, O
abdominal O
distension O
, O
upper O
respiratory O
tract O
infection O
. O

In O
addition O
, O
vomiting O
and O
fluid O
overload O
were O
reported O
in O
the O
SBS O
studies O
( O
1 O
and O
3 O
) O
at O
rates O
> O
= O
10 O
% O
. O

( O
6.1 O
) O
To O
report O
SUSPECTED O
ADVERSE O
REACTIONS O
, O
contact O
NPS O
Pharmaceuticals O
at O
1-855-5GATTEX O
( O
1-855-542-8839 O
) O
or O
FDA O
at O
1-800-FDA-1088 O
or O
www.fda.gov/medwatch O
. O

6.1 O
Clinical O
Trials O
Experience O
Because O
clinical O
trials O
are O
conducted O
under O
widely O
varying O
conditions O
, O
the O
adverse O
reaction O
rates O
observed O
can O
not O
be O
directly O
compared O
to O
rates O
in O
other O
clinical O
trials O
and O
may O
not O
reflect O
the O
rates O
observed O
in O
clinical O
practice O
. O

Across O
all O
clinical O
studies O
, O
566 O
subjects O
were O
exposed O
to O
at O
least O
one O
dose O
of O
GATTEX O
( O
190 O
patient-years O
of O
exposure O
; O
mean O
duration O
of O
exposure O
was O
17 O
weeks O
) O
. O

Of O
the O
566 O
subjects O
, O
173 O
subjects O
were O
treated O
in O
Phase O
3 O
SBS B-Not_AE_Candidate
studies O
( O
134/173 O
[ O
77 O
% O
] O
at O
the O
dose O
of O
0.05 O
mg/kg/day O
and O
39/173 O
[ O
23 O
% O
] O
at O
the O
dose O
of O
0.10 O
mg/kg/day O
) O
. O

The O
most O
commonly O
reported O
( O
> O
= O
10 O
% O
) O
adverse O
reactions O
in O
patients O
treated O
with O
GATTEX O
across O
all O
clinical O
studies O
( O
n O
= O
566 O
) O
were O
: O
abdominal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
( O
30.0 O
% O
) O
; O
injection B-OSE_Labeled_AE
site I-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
( O
22.4 O
% O
) O
; O
nausea B-OSE_Labeled_AE
( O
18.2 O
% O
) O
; O
headaches B-OSE_Labeled_AE
( O
15.9 O
% O
) O
; O
abdominal B-OSE_Labeled_AE
distension I-OSE_Labeled_AE
( O
13.8 O
% O
) O
; O
upper B-OSE_Labeled_AE
respiratory I-OSE_Labeled_AE
tract I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
( O
11.8 O
% O
) O
. O

The O
rates O
of O
adverse O
reactions O
in O
subjects O
with O
SBS B-Not_AE_Candidate
participating O
in O
two O
randomized O
, O
placebo-controlled O
, O
24-week O
, O
double-blind O
clinical O
studies O
( O
Study O
1 O
and O
Study O
3 O
) O
are O
summarized O
in O
Table O
1 O
. O

Only O
those O
reactions O
with O
a O
rate O
of O
at O
least O
5 O
% O
in O
the O
GATTEX O
group O
, O
and O
greater O
than O
placebo O
group O
, O
are O
summarized O
in O
Table O
1 O
. O

The O
majority O
of O
these O
reactions O
were O
mild O
or O
moderate O
. O

Of O
subjects O
receiving O
GATTEX O
at O
the O
recommended O
dose O
of O
0.05 O
mg/kg/day O
, O
88.3 O
% O
( O
N=68/77 O
) O
experienced O
an O
adverse O
reaction O
, O
as O
compared O
to O
83.1 O
% O
( O
49/59 O
) O
for O
placebo O
. O

Many O
of O
these O
adverse O
reactions O
have O
been O
reported O
in O
association O
with O
the O
underlying O
disease O
and/or O
parenteral O
nutrition O
. O

Table O
1 O
: O
Adverse O
reactions O
in O
> O
=5 O
% O
of O
GATTEX-treated O
SBS O
subjects O
and O
more O
frequent O
than O
placebo O
: O
Studies O
1 O
and O
3 O
Adverse O
Reaction O
Placebo O
( O
N=59 O
) O
n O
( O
% O
) O
GATTEX0.05mg/kg/day O
( O
N=77 O
) O
n O
( O
% O
) O
Abdominal B-OSE_Labeled_AE
Pain I-OSE_Labeled_AE
16 O
( O
27.1 O
) O
29 O
( O
37.7 O
) O
Upper B-OSE_Labeled_AE
Respiratory I-OSE_Labeled_AE
Tract I-OSE_Labeled_AE
Infection I-OSE_Labeled_AE
8 O
( O
13.6 O
) O
20 O
( O
26.0 O
) O
Nausea B-OSE_Labeled_AE
12 O
( O
20.3 O
) O
19 O
( O
24.7 O
) O
Abdominal B-OSE_Labeled_AE
Distension I-OSE_Labeled_AE
1 O
( O
1.7 O
) O
15 O
( O
19.5 O
) O
Vomiting B-OSE_Labeled_AE
6 O
( O
10.2 O
) O
9 O
( O
11.7 O
) O
Fluid B-OSE_Labeled_AE
Overload I-OSE_Labeled_AE
4 O
( O
6.8 O
) O
9 O
( O
11.7 O
) O
Flatulence B-OSE_Labeled_AE
4 O
( O
6.8 O
) O
7 O
( O
9.1 O
) O
Hypersensitivity B-OSE_Labeled_AE
3 O
( O
5.1 O
) O
6 O
( O
7.8 O
) O
Appetite B-OSE_Labeled_AE
Disorders I-OSE_Labeled_AE
2 O
( O
3.4 O
) O
5 O
( O
6.5 O
) O
Sleep B-OSE_Labeled_AE
Disturbances I-OSE_Labeled_AE
0 O
4 O
( O
5.2 O
) O
Cough B-OSE_Labeled_AE
0 O
4 O
( O
5.2 O
) O
Skin B-OSE_Labeled_AE
Hemorrhage I-OSE_Labeled_AE
1 O
( O
1.7 O
) O
4 O
( O
5.2 O
) O
Subjects O
with O
Stoma B-Not_AE_Candidate
Gastrointestin I-Not_AE_Candidate
al O
Stoma O
Complication O
3 O
( O
13.6 O
) O
13 O
( O
41.9 O
) O
In O
placebo-controlled O
Studies O
1 O
and O
3 O
, O
12 O
% O
of O
patients O
in O
each O
of O
the O
placebo O
and O
GATTEX O
study O
groups O
experienced O
an O
injection B-NonOSE_AE
site I-NonOSE_AE
reaction I-NonOSE_AE
. O

Adverse O
Reactions O
of O
Special O
Interest O
Malignancy B-NonOSE_AE
. O

Three O
subjects O
were O
diagnosed O
with O
malignancy B-OSE_Labeled_AE
in O
the O
clinical O
studies O
, O
all O
of O
whom O
were O
male O
and O
had O
received O
GATTEX O
0.05 O
mg/kg/day O
in O
Study O
2 O
. O

One O
subject O
had O
a O
history O
of O
abdominal O
radiation O
for O
Hodgkin B-Not_AE_Candidate
' I-Not_AE_Candidate
s I-Not_AE_Candidate
disease I-Not_AE_Candidate
two O
decades O
prior O
to O
receiving O
GATTEX O
and O
prior O
liver B-Not_AE_Candidate
lesion I-Not_AE_Candidate
on O
CT O
scan O
, O
and O
was O
diagnosed O
with O
metastatic B-OSE_Labeled_AE
adenocarcinoma I-OSE_Labeled_AE
of O
unconfirmed O
origin O
after O
11 O
months O
of O
exposure O
to O
GATTEX O
. O

Two O
subjects O
had O
extensive O
smoking O
histories O
, O
and O
were O
diagnosed O
with O
lung B-OSE_Labeled_AE
cancers I-OSE_Labeled_AE
( O
squamous I-OSE_Labeled_AE
and O
non-small O
cell I-OSE_Labeled_AE
) O
after O
12 O
months O
and O
3 O
months O
of O
GATTEX O
exposure O
, O
respectively O
. O

Colorectal B-OSE_Labeled_AE
Polyps I-OSE_Labeled_AE
. O

In O
the O
clinical O
studies O
, O
6 O
subjects O
were O
diagnosed O
with O
polyps B-OSE_Labeled_AE
of I-OSE_Labeled_AE
the I-OSE_Labeled_AE
G I-OSE_Labeled_AE
. I-OSE_Labeled_AE
I I-OSE_Labeled_AE
. I-OSE_Labeled_AE
tract I-OSE_Labeled_AE
after O
initiation O
of O
study O
treatment O
. O

In O
the O
SBS B-Not_AE_Candidate
placebo-controlled O
studies O
, O
1/59 O
( O
1.7 O
% O
) O
of O
subjects O
on O
placebo O
and O
1/109 O
( O
0.9 O
% O
) O
of O
subjects O
on O
GATTEX O
0.05 O
mg/kg/day O
were O
diagnosed O
with O
intestinal B-NonOSE_AE
polyps I-NonOSE_AE
( I-NonOSE_AE
inflammatory I-NonOSE_AE
stomal I-NonOSE_AE
and O
hyperplastic O
sigmoidal O
after O
3 O
and O
5 O
months O
, O
respectively O
) O
. O

The O
remaining O
4 O
polyp B-NonOSE_AE
cases O
occurred O
in O
the O
extension O
studies O
- O
two O
colorectal B-OSE_Labeled_AE
villous I-OSE_Labeled_AE
adenomas I-OSE_Labeled_AE
( O
onset O
at O
6 O
and O
7 O
months O
in O
GATTEX O
0.10 O
and O
0.05 O
mg/kg/day O
dose O
groups O
, O
respectively O
) O
, O
one O
hyperplastic B-OSE_Labeled_AE
polyp I-OSE_Labeled_AE
( O
onset O
6 O
months O
in O
GATTEX O
0.10 O
mg/kg/day O
dose O
group O
) O
, O
and O
one O
small O
duodenal B-OSE_Labeled_AE
polyp I-OSE_Labeled_AE
( O
onset O
at O
3 O
months O
in O
GATTEX O
0.05 O
mg/kg/day O
dose O
group O
) O
. O

Gastrointestinal B-OSE_Labeled_AE
Obstruction I-OSE_Labeled_AE
. O

Overall O
, O
12 O
subjects O
experienced O
one O
or O
more O
episodes O
of O
intestinal B-OSE_Labeled_AE
obstruction I-OSE_Labeled_AE
/stenosis O
: O
6 O
in O
SBS B-Not_AE_Candidate
placebo-controlled O
studies O
and O
6 O
in O
the O
extension O
studies O
. O

The O
6 O
subjects O
in O
the O
placebo-controlled O
trials O
were O
all O
on O
GATTEX O
: O
3/77 O
( O
3.9 O
% O
) O
on O
GATTEX O
0.05 O
mg/kg/day O
and O
3/32 O
( O
9.4 O
% O
) O
on O
GATTEX O
0.10 O
mg/kg/day O
. O

No O
cases O
of O
intestinal B-NonOSE_AE
obstruction I-NonOSE_AE
occurred O
in O
the O
placebo O
group O
. O

Onsets O
ranged O
from O
1 O
day O
to O
6 O
months O
. O

In O
the O
extension O
studies O
, O
6 O
additional O
subjects O
( O
all O
on O
GATTEX O
0.05 O
mg/kg/day O
) O
were O
diagnosed O
with O
intestinal B-OSE_Labeled_AE
obstruction/ O
stenosis I-OSE_Labeled_AE
with O
onsets O
ranging O
from O
6 O
days O
to O
7 O
months O
. O

Two O
of O
the O
6 O
subjects O
from O
the O
placebo-controlled O
trials O
experienced O
recurrence O
of O
obstruction O
in O
the O
extension O
studies O
. O

Of O
all O
8 O
subjects O
with O
an O
episode O
of O
intestinal B-OSE_Labeled_AE
obstruction/ O
stenosis I-OSE_Labeled_AE
in O
these O
extension O
studies O
, O
1 O
subject O
required O
endoscopic O
dilation O
and O
none O
required O
surgical O
intervention O
. O

Gallbladder B-NonOSE_AE
, O
Biliary O
and O
Pancreatic O
Disease I-NonOSE_AE
. O

For O
gallbladder B-NonOSE_AE
and O
biliary O
disease I-NonOSE_AE
in O
the O
placebo-controlled O
studies O
, O
3 O
subjects O
were O
diagnosed O
with O
cholecystitis B-OSE_Labeled_AE
, O
all O
of O
whom O
had O
a O
prior O
history O
of O
gallbladder B-Not_AE_Candidate
disease I-Not_AE_Candidate
and O
were O
in O
the O
GATTEX O
0.05 O
mg/kg/day O
dose O
group O
. O

No O
cases O
were O
reported O
in O
the O
placebo O
group O
. O

One O
of O
these O
3 O
cases O
had O
gallbladder B-OSE_Labeled_AE
perforation I-OSE_Labeled_AE
and O
underwent O
cholecystectomy O
the O
next O
day O
. O

The O
remaining O
2 O
cases O
underwent O
elective O
cholecystectomy O
at O
a O
later O
date O
. O

In O
the O
extension O
studies O
, O
3 O
subjects O
had O
an O
episode O
of O
acute B-OSE_Labeled_AE
cholecystitis I-OSE_Labeled_AE
; O
2 O
subjects O
had O
new-onset O
cholelithiasis B-OSE_Labeled_AE
; O
and O
1 O
subject O
experienced O
cholestasis B-NonOSE_AE
secondary O
to O
an O
obstructed B-Not_AE_Candidate
biliary I-Not_AE_Candidate
stent I-Not_AE_Candidate
. O

For O
pancreatic B-NonOSE_AE
disease I-NonOSE_AE
in O
the O
placebo-controlled O
studies O
, O
1 O
subject O
( O
GATTEX O
0.05 O
mg/kg/day O
dose O
group O
) O
had O
a O
pancreatic B-OSE_Labeled_AE
pseudocyst I-OSE_Labeled_AE
diagnosed O
after O
4 O
months O
of O
GATTEX O
. O

In O
the O
extension O
studies O
, O
1 O
subject O
was O
diagnosed O
with O
chronic B-OSE_Labeled_AE
pancreatitis I-OSE_Labeled_AE
; O
and O
1 O
subject O
was O
diagnosed O
with O
acute B-OSE_Labeled_AE
pancreatitis I-OSE_Labeled_AE
. O

Fluid B-NonOSE_AE
Overload I-NonOSE_AE
. O

In O
the O
placebo-controlled O
trials O
, O
fluid B-OSE_Labeled_AE
overload I-OSE_Labeled_AE
was O
reported O
in O
4/59 O
( O
6.8 O
% O
) O
of O
subjects O
on O
placebo O
and O
9/77 O
( O
11.7 O
% O
) O
subjects O
on O
GATTEX O
0.05 O
mg/kg/day O
. O

Of O
the O
9 O
cases O
in O
the O
GATTEX O
group O
, O
there O
were O
2 O
cases O
of O
congestive B-OSE_Labeled_AE
heart I-OSE_Labeled_AE
failure I-OSE_Labeled_AE
( O
CHF O
) O
, O
1 O
of O
whom O
was O
reported O
as O
a O
serious O
adverse O
event O
and O
the O
other O
as O
non-serious O
. O

The O
serious O
case O
had O
onset O
at O
6 O
months O
, O
and O
was O
possibly O
associated O
with O
previously O
undiagnosed O
hypothyroidism B-Not_AE_Candidate
and/or O
cardiac B-Not_AE_Candidate
dysfunction I-Not_AE_Candidate
. O

Concomitant O
Oral O
Medication O
. O

GATTEX O
can O
increase O
the O
absorption O
of O
concomitant O
oral O
medications O
such O
as O
benzodiazepines O
and O
psychotropic O
agents O
. O

In O
the O
placebo-controlled O
trials O
, O
an O
analysis O
of O
episodes O
of O
cognition B-NonOSE_AE
and O
attention O
disturbances I-NonOSE_AE
was O
performed O
for O
subjects O
on O
benzodiazepines O
. O

One O
of O
the O
subjects O
in O
the O
GATTEX O
0.05 O
mg/kg/day O
group O
( O
on O
prazepam O
) O
experienced O
dramatic O
deterioration B-NonOSE_AE
in I-NonOSE_AE
mental I-NonOSE_AE
status I-NonOSE_AE
progressing O
to O
coma B-NonOSE_AE
during O
her O
first O
week O
of O
GATTEX O
therapy O
. O

She O
was O
admitted O
to O
the O
ICU O
where O
her O
benzodiazepine O
level O
was O
> O
300 O
mcg/L O
. O

GATTEX O
and O
prazepam O
were O
discontinued O
, O
and O
coma B-NonOSE_AE
resolved O
5 O
days O
later O
. O

6.2 O
Immunogenicity O
Consistent O
with O
the O
potentially O
immunogenic B-NonOSE_AE
properties O
of O
medicinal O
products O
containing O
peptides O
, O
administration O
of O
GATTEX O
may O
trigger O
the O
development B-OSE_Labeled_AE
of I-OSE_Labeled_AE
antibodies I-OSE_Labeled_AE
. O

In O
a O
randomized O
, O
double-blind O
, O
placebo-controlled O
, O
parallel-group O
, O
multi-national O
, O
multi-center O
, O
clinical O
trial O
( O
Study O
1 O
) O
in O
adults O
with O
SBS O
, O
the O
incidence O
of O
anti B-OSE_Labeled_AE
- I-OSE_Labeled_AE
GATTEX I-OSE_Labeled_AE
antibody I-OSE_Labeled_AE
was O
0 O
% O
( O
0/16 O
) O
at O
Week O
12 O
and O
18 O
% O
( O
6/34 O
) O
at O
Week O
24 O
in O
subjects O
who O
received O
subcutaneous O
administration O
of O
0.05 O
mg/kg O
GATTEX O
once O
daily O
. O

The O
anti B-OSE_Labeled_AE
- I-OSE_Labeled_AE
GATTEX I-OSE_Labeled_AE
antibodies I-OSE_Labeled_AE
were O
cross-reactive O
to O
native O
glucagon-like O
peptide O
( O
GLP-2 O
) O
in O
five O
of O
the O
six O
subjects O
( O
83 O
% O
) O
who O
had O
anti B-OSE_Labeled_AE
- I-OSE_Labeled_AE
GATTEX I-OSE_Labeled_AE
antibodies I-OSE_Labeled_AE
. O

In O
the O
extension O
study O
( O
Study O
2 O
) O
, O
the O
immunogenicity B-OSE_Labeled_AE
incidence O
rate O
increased O
over O
time O
to O
27 O
% O
( O
14/51 O
) O
at O
12 O
months O
and O
38 O
% O
( O
13/34 O
) O
at O
18 O
months O
. O

Anti B-NonOSE_AE
- I-NonOSE_AE
GATTEX I-NonOSE_AE
antibodies I-NonOSE_AE
appear O
to O
have O
no O
impact O
on O
short O
term O
( O
up O
to O
1.5 O
years O
) O
efficacy O
and O
safety O
although O
the O
long-term O
impact O
is O
unknown O
. O

A O
total O
of O
40 O
subjects O
were O
tested O
for O
neutralizing B-NonOSE_AE
antibodies I-NonOSE_AE
- O
20 O
of O
these O
subjects O
had O
no O
neutralizing B-NonOSE_AE
antibodies I-NonOSE_AE
, O
and O
the O
remaining O
20 O
subjects O
had O
no O
detectable O
neutralizing B-NonOSE_AE
antibodies I-NonOSE_AE
although O
, O
the O
presence O
of O
teduglutide O
at O
low O
levels O
in O
these O
study O
samples O
could O
have O
resulted O
in O
false O
negatives O
( O
no O
neutralizing B-NonOSE_AE
antibody I-NonOSE_AE
detected I-NonOSE_AE
although O
present O
) O
. O

Immunogenicity B-NonOSE_AE
assay O
results O
are O
highly O
dependent O
on O
the O
sensitivity O
and O
specificity O
of O
the O
assay O
and O
may O
be O
influenced O
by O
several O
factors O
such O
as O
: O
assay O
methodology O
, O
sample O
handling O
, O
timing O
of O
sample O
collection O
, O
concomitant O
medication O
, O
and O
underlying O
diseases O
. O

For O
these O
reasons O
, O
comparison O
of O
the O
incidence O
of O
antibodies B-NonOSE_AE
to I-NonOSE_AE
GATTEX I-NonOSE_AE
with O
the O
incidence O
of O
antibodies B-NonOSE_AE
to I-NonOSE_AE
other I-NonOSE_AE
products I-NonOSE_AE
may O
be O
misleading O
. O

